Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ribavirin ANDAs Clear FDA; Schering Goes Generic Too

Executive Summary

Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol

You may also be interested in...



Brand Firm In-House Generics Unlikely To Grab Large Market Share – Analyst

Brand companies that launch their own generics are unlikely to capture significant market share but will exert pricing pressure on the ANDA first-filer, a Lehman Brothers analyst said

Brand Firm In-House Generics Unlikely To Grab Large Market Share – Analyst

Brand companies that launch their own generics are unlikely to capture significant market share but will exert pricing pressure on the ANDA first-filer, a Lehman Brothers analyst said

Pfizer Accupril “Branded Generic” Plans Challenged By Teva

Pfizer should be required to obtain a supplemental NDA approval for Accupril before marketing a "branded generic" version of the ACE inhibitor, Teva told FDA in a June 9 1citizen petition

Related Content

UsernamePublicRestriction

Register

PS043733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel